Molecular Partners AG announced the appointment of Martin Steegmaier, Ph.D. as Chief Scientific Officer (CSO) and member of the company?s Executive Committee, effective October 1, 2025. Martin brings a wealth of experience in oncology drug development, having previously contributed to the advancement of several innovative cancer therapies at major biotech and pharmaceutical companies. Martin Steegmaier joins Molecular Partners from SOTIO Biotech, a clinical-stage company developing immunotherapies for cancer, where he was CSO and lead the development of a broad pipeline of oncology programs. Martin has extensive experience from senior roles at major biotech and pharma companies, including as Head of Research at MorphoSys, focusing on the development of antibody-based therapeutics in immuno-oncology and hematology-oncology.
He previously held various positions in pharma partnering and oncology disease areas at Roche, becoming Head of Discovery for the Large Molecule Research organization at the Roche Innovation Center in Munich, and at Boehringer Ingelheim in oncology drug discovery. Martin graduated from the Northern Arizona University and holds a Ph.D. in biochemistry from the University of Basel and an MBA from the Edinburgh Business School.
